Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Int J Artif Organs. 2022 Aug;45(8):672-679. doi: 10.1177/03913988221105903. Epub 2022 Jun 16.
Several studies have reported the feasibility of urgent-start peritoneal dialysis (PD) as an alternative to hemodialysis (HD) using a central venous catheter (CVC). However, the cost-effectiveness of automated peritoneal dialysis (APD) as an urgent-start dialysis modality has not been directly evaluated, especially in China.
We prospectively enrolled patients with end-stage renal disease (ESRD) who required urgent-start dialysis at a single center from March 2019 to November 2020. Patients were grouped according to their urgent-start dialysis modality (APD and HD). Urgent-start dialysis conducted until 14 days after PD catheter insertion. Then, PD was maintained. Each patient was followed until July 2021 or death or loss to follow-up. The primary outcome was the incidence of short-term dialysis-related complications. The secondary outcome was the cost and duration of the initial hospitalization. Technique survival, peritonitis-free or bacteriamia-free survival and patient survival were also compared.
Sixty-eight patients were included in the study, of whom 36 (52.9%) patients were in APD group. Mean follow-up duration was 20.1 months. Compared with the HD group, the APD group had significantly fewer short-term dialysis-related complications. The cost of initial hospitalization was also significantly lower in APD patients. There was no significant difference between APD and HD patients with respect to duration of the initial hospitalization, technique survival rate, peritonitis-free or bacteriemia-free survival rate, and patient survival rate.
Among ESRD patients with an urgent need for dialysis, APD as urgent-start dialysis modality, compared with HD using a CVC, resulted in fewer short-term dialysis-related complications and lower cost.
多项研究已经报道了使用中心静脉导管(CVC)进行紧急开始腹膜透析(PD)作为血液透析(HD)替代方案的可行性。然而,自动化腹膜透析(APD)作为紧急开始透析方式的成本效益尚未得到直接评估,特别是在中国。
我们前瞻性地招募了 2019 年 3 月至 2020 年 11 月在一家中心需要紧急开始透析的终末期肾病(ESRD)患者。根据他们的紧急开始透析方式(APD 和 HD)将患者分组。紧急开始透析持续到 PD 导管插入后 14 天。然后,继续进行 PD。每位患者随访至 2021 年 7 月或死亡或失访。主要结局是短期透析相关并发症的发生率。次要结局是初始住院的费用和持续时间。还比较了技术生存率、腹膜炎无或菌血症无生存率和患者生存率。
该研究共纳入 68 例患者,其中 36 例(52.9%)患者在 APD 组。平均随访时间为 20.1 个月。与 HD 组相比,APD 组短期透析相关并发症明显较少。APD 患者的初始住院费用也明显较低。APD 和 HD 患者在初始住院时间、技术生存率、腹膜炎无或菌血症无生存率和患者生存率方面无显著差异。
在有紧急透析需求的 ESRD 患者中,与使用 CVC 的 HD 相比,APD 作为紧急开始透析方式可减少短期透析相关并发症并降低成本。